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Abstract
Background: Excessive secretion of IL-8 characterizes cystic fibrosis (CF). This has been attributed to excessive
activation of epithelial cell I-B Kinase and/or NFB. Maximum IL-8 production requires 3 cooperative mechanisms:
1) release of the promoter from repression; 2) activation of transcription by NFB and AP-1; 3) stabilization of
mRNA by p38-MAPK. Little is known about regulation of IL-8 by MAPKs or AP-1 in CF.
Methods: We studied our hypothesis in vitro using 3-cellular models. Two of these models are transformed cell
lines with defective versus normal cystic fibrosis transmembrane conductance regulator (CFTR) expression: an
antisense/sense transfected cell line and the patient derived IB3-1/S9. In the third series of studies, we studied
primary necropsy human tracheal epithelial cells treated with an inhibitor of CFTR function. All cell lines were
pretreated with parthenolide and then stimulated with TNFa and/or IL-1b.
Results: In response to stimulation with TNFa and/or IL-1b, IL-8 production and mRNA expression was greater in
CF-type cells than in non-CF controls. This was associated with enhanced phosphorylation of p38, ERK1/2 and JNK
and increased activation of AP-1. Since we previously showed that parthenolide inhibits excessive IL-8 production
by CF cells, we evaluated its effects on MAPK and AP-1 activation and showed that parthenolide inhibited ERK and
AP-1 activation. Using a luciferase promoter assay, our studies showed that parthenolide decreased activation of
the IL-8 promoter in CF cells stimulated with TNFa/IL-1b.
Conclusions: In addition to NFB MAPKs ERK, JNK and p38 and the transcription factor AP-1 are also dysregulated
in CF epithelial cells. Parthenolide inhibited both NFB and MAPK/AP-1 pathways contributing to the inhibition of
IL-8 production.
Introduction
Cystic fibrosis (CF) is characterized by repeated and
progressive airways infection, inflammation, and
obstruction. It is now clear that the immune and inflam-
matory responses in CF lung are disproportionate to the
threat posed by infection [1-6]. Bronchoalveolar lavage
(BAL) fluid from patients with CF contains higher con-
centrations of IL-8 and PMN than BAL from patients
without CF but with similar burdens of bacteria or LPS
[7-9]. Considerable evidence indicates that activation of
NFB is prolonged and excessive in epithelial cell lines,
mice and humans with defective CFTR expression or
function [5,6,10-14]. NFB clearly plays a key role in the
regulation of expression of pro-inflammatory cytokines,
chemokines and mucins which are important in CF.
However, despite its major role; it is unlikely that NFB
alone should be sufficient for maximal transcriptional
activation or induction of all the genes that are involved
in this complex disease. Several studies suggest that
expression of IL-8 is subject to multiple and coordinated
regulation by mitogen activated protein kinases
(MAPKs) and AP-1, in addition to NFB [12,15-17].
Holtmann and colleagues have proposed a model in
which the extent of IL-8 production is the net result of
3 regulatory mechanisms: 1) release of the promoter
from repression; 2) transcriptional activation by NFB
and AP-1; and 3) stabilization of mRNA by p38 MAPK
[16]. IL-8 gene expression is also regulated in part
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through remodeling of chromatin structure which is
under the control of various changes including histone
acetylation and DNA methylation [18-20]. Recently, we
showed that parthenolide, a naturally occurring sesqui-
terpene lactone from the medicinal plant feverfew, inhi-
bits IB kinase (IKK), NFB activation and IL-8
secretion by CF epithelial cells [14].
Very few studies focused on MAPKs activity [12,15]
but none of these showed the prolonged activation of
the MAPKs that could explain the prolonged and unre-
solved inflammatory responses documented in CF
patient. Moreover, to our knowledge no study has
shown excessive or prolonged activation of AP-1 in CF.
In the present study, we investigated the following two
hypotheses: 1) To determine if the signaling pathway
going through the MAPKs: p38, extracellular-regulated
protein kinase (ERK), and Jun-N terminal protein kinase
(JNK) to the transcription factor activator-protein-1
(AP-1) signaling is dysregulated in CF epithelial cells; 2)
To determine whether this pathway can be manipulated
by parthenolide. To study MAPKs and AP-1 involve-
ment in CF epithelial IL-8 production we used 3 differ-
ent CF epithelial cell models and their corresponding
controls. The first model is the human bronchial epithe-
lial cell line16 HBE, stably transfected with antisense oli-
gonucleotides, inhibiting the expression of CFTR (AS).
The control for this cell line is 16HBE cells stably trans-
fected with sense oligonucleotides (S). The second
model uses cells obtained from a patient with CF, this is
designated IB3 and the control cell line which has been
corrected with full-length CFTR, this is designated S9
[22]. The third model involved using human primary




We used two different sets of cell lines with CF defects
and their corresponding controls (Table 1). The first
was 16 HBE human bronchial epithelial cell line stably
transfected with an anti-sense (AS) oligonucleotide
which inhibits expression of CFTR; and a sister cell line
transfected with CFTR sense oligonucleotide, (S) as the
control. These have been described previously [21] and
were kindly provided by Dr. Pamela Davis (Case Wes-
tern Reserve University, Cleveland). The second was
IB3-1 cells from a patient with CF, and the control cell
line, S9 cells, which was rescued from CFTR deficiency
by stable transfection with full-length functional CFTR
[22]. Cells were maintained in a 5% CO2 incubator at
37°C using MEM (Mediatech, Inc. Herndon, VA) for AS
and S cell lines and LHC-8 media (Biosource, Camarillo,
CA) for IB3-1 and S9 cell lines. All media contained
penicillin/streptomycin and 10% fetal bovine serum.
We also used human tracheal epithelial cells (HTE)
recovered from necropsy specimens, as previously
described [21]. Cells were grown in an air-liquid inter-
face (ALI) on collagen-coated, semi-permeable mem-
brane as previously described. Cells were allowed to
differentiate for 3 to 4 weeks, then switched to liquid-
liquid interface, (LLI) and treated with either DMSO
1:1000 (vehicle control) or 20 μM CFTRinh172 [21].
Drugs were added to both the apical and basolateral
sides and refreshed every 24 hours. After 72 hours, cells
were pretreated with 15 μM parthenolide or vehicle
alone for 1 hour before treatment with TNFa at 100
ng/ml for 3 h. The HTE cells were all from the same
donor specimens. Six filters were used for DMSO and
six with CFTRinh172.
Experimental conditions
Cell lines were plated at 2 × 106 cells/well on vitrogen-
coated 6-well plates. Twenty-four hours after plating,
the cells were switched to serum-free medium for 18 h.
IL-8 production was induced by treating AS and S cells
with TNFa (100 ng/ml, Sigma St. Louis, MO) with or
without IL-1b (100 ng/ml, Sigma St. Louis, MO), and
IB3-1 and S9 with TNFa at 30 ng/ml [2,14]. Viability
and possible cytotoxicity of the cytokines were deter-
mined by trypan blue exclusion [14]. As in our previous
studies, cell lines were pretreated with 40 μM partheno-
lide for AS and S and 15 μM for IB3-1 and S9 (Sigma,
St. Louis, MO) [14] for 1 h before treatment with TNFa
and/or IL-1b. Parthenolide was dissolved in dimethyl-
sulfoxide (DMSO), such that the final maximum con-
centration of DMSO in the experimental media was
0.04%. Controls contained the same concentration of
DMSO. At various times, media were harvested and
assayed for IL-8 (R&D Systems, Minneapolis, MN).
Unstimulated controls were run in each experiment.
After removal of media, the epithelial cell monolayers
were washed with ice cold PBS and harvested by
Table 1 Cell Lines
CF Wild Type
AS (16HBE stably transfected with an anti-sense oligonucleotide) S (16HBE stably transfected with CFTR sense oligonucleotide)
IB3-1 (CF patient) S9 (CF patient-transfected with full length CFTR)
HTE+CFTRinh172 (necropsy human tracheal epithelial treated with CFTR inhibitor
172)
HTE+DMSO (necropsy human tracheal epithelial treated with
DMSO)
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scraping, then pelleted at 600 × g for 5 min at 4°C.
Separate cytosolic and nuclear proteins extracts were
prepared according to manufacturer’s instructions (Bio-
Vision Research products, Mountain View, CA). Extracts
were then used for analysis of NFB and AP-1. In
another set of experiment cells were lysed using Phos-
phoSafe (Novagen, Madison, WI) containing protease
and phosphatase inhibitors. Protein concentrations were
determined using the Bradford method (Bio-Rad
Laboratories) and data for IL-8 production were
expressed as pg/mg cellular protein.
RNA isolation, reverse transcription and real-time PCR
RNA was extracted using Trizol or the RNeasy® Mini
kit (Qiagen). For reverse transcription, 5 μg total RNA
was adjusted to 8 μl. One μl of oligo (dt) (0.5 μg/μl) and
1 μl dNTP mix (10 mM each) were added. The mixtures
were denatured at 65°C for 5 min and chilled on ice.
cDNA was produced by adding a mixture containing
200 mM Tris-HCl, pH 8.4, 500 mM KCl), MgCl2, DTT,
1 μl RNase OUT, and 1 μl Superscript ™ II reverse
transcriptase. The samples were incubated at 42°C for
50 min and at 70°C for 15 min then chilled on ice.
RNase H (1 ul) was added, followed by incubation at 37°
C for 20 min. The cDNA solution was subsequently
diluted 20 times with water and stored at -80°C. Primers
were designed using Primer Express software (Applied
Biosystems, Foster City, CA). Transcript levels were nor-
malized using the housekeeping gene GAPDH. We have
previously determined that GAPDH expression is con-
stitutive in the cell lines and was not s not altered by
TNF-a or IL-1b treatment (data not shown). Samples
were run in triplicate on an ABI Prism 7700 sequence
detector (Applied Biosystems, Foster City, CA) accord-
ing to the manufacturer’s instructions for 40 cycles, and
the average threshold cycle (Ct) was determined.
Changes in IL-8 mRNA levels were expressed as ΔCt
and ΔΔCt and the expression level of IL-8 gene was
represented as fold increase: 2-ΔΔCT, where ΔΔCt =
[ΔCtsample stimulated)] - [ΔCt sample unstimulated] and ΔCt =
[Ctsample]- [CtGAPDH].
Electrophoretic Mobility Shift Assay (EMSA)
Aliquots of nuclear extracts from cell lines (5 μg) were
suspended in binding buffer [10 mM Tris-HCl, pH 7.5,
1 mM MgCl2, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM
DTT, 4% glycerol, 0.5 μg poly (dI-dC)] at room tem-
perature for 10 min then incubated for an additional 20
min with 32P-radiolabeled consensus oligonucleotides:
5’AGTTGAGGGGACTTTCCCAGGC-3’ for NFkB
assays 5’-CGCTTGATGAGTCAGCCGGAA-3’ for AP-1
(both from Promega, Madison, WI). Protein binding of
the oligonucleotides was analyzed using 6% non-dena-
tured PAGE and autoradiography [14]. Cold competitors
were used to assure the specificity of binding of each
oligonucleotide. A Panomics Luminex based kit was also
used to study NFB and AP-1 activation, according to
manufacturer’s instructions (Panomics Fremont, CA).
Immunoblotting for MAP kinases: ERK, JNK and p38
Aliquots of cell extracts (15 μg protein) were separated
by 10% SDS-PAGE and transferred onto nitrocellulose
membrane. The western blots were probed using rabbit
polyclonal antibodies specific for phosphorylated and
total p38, JNK and ERK (Cell Signaling, Inc., Beverly
MA) and immunoreactive proteins were visualized by
enhanced chemiluminescence [5,6,14]. Blots were also
probed with monoclonal anti-b-actin to assure equal
protein loading.
Transfection and luciferase promoter assays
AS and S cell lines were cotransfected with firefly luci-
ferase construct dependent on the IL-8 promoter, and a
reporter plasmid mediating constitutive expression of
Renilla luciferase as a transfection control [23]. Cells
were lysed for measurement of firefly and Renilla luci-
ferase activities using reagents from Promega as pre-
viously described. Firefly luciferase activity was
normalized by comparison to the Renilla luciferase
activity in the same sample.
Statistical Analysis
For cytokine data, 0 was assigned to values below the
limit of detection of the ELISA assays. All data are
expressed as mean ± SEM. Data were compared using
the student’s t-test. Comparisons between CF and wild
type with/without stimulations, 95% confidence interval,
significance p ≥ 0.05. Data is product of 3 to 4 different
experiments with n = 4 to 8 per each time point and
condition.
Results
Loss of CFTR Results in high accumulation of IL-8 mRNA
CF cell lines stimulated by TNFa/IL-1b secreted much
greater concentrations of IL-8 than similarly stimulated
non-CF cells. We previously reported that this was asso-
ciated with increased and persistent activation of IKK
and NFB in the AS cells as compared to S cells [2,14].
In this study, we determined the expression of IL-8
mRNA in AS/S and IB3-1/S9 cell lines in response to
IL-1b and/or TNFa by real time PCR. The mRNA con-
tents were normalized for GAPDH and the results are
given in relative units. Following treatment with TNFa/
IL-1b, IL-8 mRNA was significantly higher in AS cells
compared to S cells (Figure 1A). At 3 h post stimula-
tion, and in accordance with the high production of IL-
8 protein (Figure 1 inset), IL-8 mRNA was increased by
more than 85 fold in AS cells (p = 0.003), while in S
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Figure 1 IL-8 expression and production by “CF like” like (Solid bars)-and “wild-type like” cells (open bars) upon stimulation with IL-
1b and/or TNFa. IL-8 mRNA expression was evaluated by real time-PCR. (A) IL-8 mRNA were significantly higher in AS cells at 3 and 6 h (p =
0.003 and p = 0.0002 respectively) and (B) in IB3-1 cells at 3 h (p = 0.0007). The media were also collected and subject to ELISA to determine IL-
8 production. Similarly to the content of IL-8 mRNA, IL-8 protein were significantly high in AS cells at 3 and 6 h (p = 0.004 and p = 0.003
respectively) compared to S cells (A, inset).
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cells the increase was only 33 fold (Figure 1A) when
compared to their non-stimulated baseline controls. At
6 h after stimulation, IL-8 mRNA was still elevated by
56 fold in the AS cells (p = 0.0002), as compared to 26-
fold in the S cells when compared to their non-stimu-
lated baseline controls. Similarly IB3-1 cells also
increased IL-8 mRNA accumulation much more than S9
cells (Figure 1B). At 3 h post stimulation IL-8 mRNA
was increased by more than 1500 fold in IB3-1 cells (p
= 0.0007) while in S9 cells the increase was only 400
fold, when compared to their non-stimulated baseline
controls. At 6 h after stimulation IL-8 mRNA was still
elevated by 600 fold in the IB3-1 cells as compared to
350 fold in the S9 cells compared to baseline controls.
TNF-a and/or IL-1b causes increased activation of AP-1 in
CF as compared to control cells
Recently, there have been major advances in understand-
ing how different signaling pathways coordinately regu-
late IL-8 transcription and mRNA stabilization in
response to external stimuli. Besides its binding sites for
NFB, the IL-8 promoter also contains binding sites for
activator protein-1 (AP-1), which is not essential for
baseline expression but is required for maximal expres-
sion of IL-8 [16,17,24,25]. To understand how the two
transcription factors might contribute to the tremendous
increase in IL-8 protein secretion by CF epithelial cells,
we studied the activation of AP-1 as well as NFB. As
reported previously, and shown here as a positive control,
unstimulated AS and S cells have little detectable active
nuclear NFB (Figure 2A, time 0). However, stimulation
with TNFa/IL-1b increased binding of NFB by 15 min
in both cell types (Figure 2A, B). In AS cells, the increase
in NFB activation was significantly higher at 30 and 60
min (p = 0.001 and p = 0.007, respectively). The same
phenomenon was observed with the IB3 and S9 model.
TNFa stimulation significantly increased NFB binding
at 30 minutes (Figure 2B). However, the NFB levels of
activation were comparable between the IB3 (CF cells)
and S9 (controls) at 60 minute, potentially related to the
different origins of the cell lines. The AS/S and IB3/S9
models from the same studies were also evaluated for
AP-1 activation post-TNFa stimulation. Baseline AS/S
and IB3/S9 cells had little or no nuclear AP-1 (Figure 2C
and 2D, time 0). Incubation with TNFa/IL-1b increased
AP-1 activation significantly in both AS (p = 0.002) and
IB3 (p = 0.05) cell lines by 30 min Similarly, the elevated
levels of AP-1 in AS cells were sustained out to 180 min-
utes consistent with the NFB studies, with the IB3 com-
parable with the S9 cells (Figures 2C and 2D). These data
suggest that both NFB and AP-1 activation is dysregu-
lated in CF epithelial cells, potentially contributing to the
excessive IL-8 message expression and protein secretion
observed under these conditions.
TNFa- and/or IL-1b-induces over-activation of p38, ERK
and JNK in cells with defective CFTR expression
Because AP-1 is activated by mitogen-activated protein
kinases (MAPKs) [17,26,27], we sought to determine
whether activation of these enzymes might be associated
with AP-1 activation in the CF cells. MAPK Phospho-
p38, JUN-N terminal protein kinase (JNK), and the
extracellular-regulated protein kinase (ERK) cascades are
active by phosphorylation through dual specificity
MAPK kinases (MKK) and may all contribute to IL-8
expression. We found no difference in baseline ERK-
phosphorylation between b AS and S cell lines (time 0,
Figure 3A). TNFa/IL-1b stimulation of AS cells resulted
in ERK phosphorylation at all time points. ERK phos-
phorylation was significantly increased in AS cells at 30
and 180 min (p = 0.05)) (Figure 3B, solid bars), while it
was markedly reduced by 30 min and barely detectable
at 60 and 180 min in the S cells (Figure 3B, open bars).
Figure 3A shows marked increases in phosphorylated
p38 at in the AS cells after 15 and 30 minutes post-sti-
mulation with TNFa/IL-1b, which was only modest in
the S cells. A similar pattern was observed for the phos-
phorylation of the p54 and p46 isoform of JNK (Figures
3A and 3C). Phospho-p54 was significantly increased in
AS cells at 15 and 30 min (p = 0.04 and p = 0.01,
respectively) (Figure 3C, solid pars). Phospho-p46 was
also significantly high in AS cells at 15 and 30 min (p =
0.04 and p = 0.01, respectively) as compared to control
S cells (Figure 3C, hatched bars). In all cases TNFa/IL-
1b stimulation did not alter the total amounts of these
proteins (data not shown) suggesting that the treatment
change activity of the MAPKs rather than the abun-
dance of the proteins. In comparison to AS cells, all 3
MAPKs were significantly elevated in IB3-1 cells. Figure
3D shows that ERK phosphorylation is very significant
at the baseline in IB3-1 cells (time 0, p = 0.01) com-
pared to S9 cells. TNFa stimulation significantly
increased phospho-ERK in IB3-1 at 30 min (p = 0.04)
(Figure 3D, solid bars). Phospho-p38 was significantly
increased in TNFa stimulated IB3-1 cells at 15 and 30
min (Figure 3E, p = 0.003 and p = 0.01, respectively)
(Figure 3E, solid bars). Figure 3F, shows a significant
elevation in phospho-JNK at all-time point in IB3-1 cells
at 15, 30 and 60 min (p = 0.00004, p = 0.01 and p =
0.05 respectively) compared to control S9 cells.
Parthenolide inhibits TNFa/IL-1b-induced activation/
nuclear translocation of AP-1
Parthenolide is an anti-inflammatory drug thought to be
able to suppress inflammation through inhibiting NFB,
amongst other effects [14]. The observed differences in
MAPKs activity opened new questions about the
mechanisms of parthenolide’s effects in CF cells. There-
fore, we sought to determine if the inhibitory activities
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of parthenolide also extended to the MAPK-AP-1 path-
way. AS and S cells were pretreated with parthenolide
then stimulated with TNFa/IL-1b as in Figure 1 and 2.
Nuclear extracts were prepared and DNA-binding activ-
ity of AP-1 was measured by EMSA. For comparison,
NFB was also assayed. The inhibition of NFB activa-
tion by parthenolide was similar to what we reported
previously [14]. Parthenolide pretreatment inhibits sig-
nificantly NFB activation in AS cells at 15, 30 and 60
min (p = 0.003, p = 0.003 and p = 0.004, respectively)
(Figure 4A and 4B). Pretreatment with parthenolide also
inhibits significantly AP-1 activation in AS at 30 min (p
= 0.04) (Figure 4C and 4D). Densitometry of the parthe-
nolide inhibitor effect on NFB and AP-1 activity in
IB3-cells with (white bars) and without (solid bars)
parthenolide is shown (Figures 4E and 4F).
Parthenolide inhibited ERK1/2 and JNK phosphorylation
and stabilized p38 phosphorylation
We hypothesized that parthenolide’s inhibition of AP-1
activation might be due to inhibition of the upstream
MAPKs which activate this transcription factor. Because
the p38 MAPK pathway is also believed to regulate a spe-
cific, post-transcriptional step in IL-8 mRNA processing,
we focused on determining if parthenolide alters p38-
phosphorylation [16,17]. Since MAPKs ERK and JNK acti-
vate AP-1, we also evaluated the effect of parthenolide on
their activation. Figures 5A and 5B show that pretreatment
Figure 2 Loss of CFTR Results in high activation of the transcription factors NFB and AP-1. AS and S cells were incubated in serum free
media for 18 h then were stimulated with TNFa/IL-1b for the indicated time. Subsequently, nuclear extracts were prepared then analyzed for
NFB (A, B) and AP-1 (C, D). Cells not stimulated with TNFa/IL-1b are shown as 0 time. A and C; The amount of complexed NFB and AP-1
probe respectively estimated by image scanning and expressed in arbitrary units. Results are shown as mean ± SEM of three separate
experiments (n = 5-6 for each time point and condition). Solid bars, AS cells and open bars S cells. NFB. AP-1 activation was significantly
increased in AS cells at 15 and 30 min after TNFa/IL-1b stimulation (p = 0.003 and p = 0.0002, respectively) compared to S cells.
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Figure 3 Activation of MAPKs in IL-1b and/or TNFa stimulated AS/S and IB3-1/S9 cells. Both pair of cell lines were incubated in serum
free media for 18 h then stimulated with IL-1b and/or TNFa for the indicated time points. At the indicated time media was removed and cells
washed then total cell extracts were prepared which serve to perform western blot to detected phosphorylation and total protein of the MAPKs
ERK, p38 and JNK in AS and S cells (A, B, C, D, respectively), and IB3-1 and S9 cells (E, F, G, respectively). Summary graph of data for MAPKs
phosphorylation determined by image analysis of densitometry from autoradiographs. Data show mean ± SEM of scan area of pERK, pp38 and
pJNK (n = 5 to 8 in each time point and condition) corrected for scan area of b-actin in the same gel lane.
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with parthenolide inhibited phosphorylation and activation
of ERK 1 and 2 at 15 and 30 min and the inhibition was
significant at 30 min (p = 0.05). In contrast, parthenolide
stabilized the phosphorylation of JNK, especially p46 at 30
and 60 min (p = 0.01 and p = 0.006, respectively) (Figure
5C and 5D, open bars), and the phosphorylated of JNK-
p54 was not significantly different after parthenolide pre-
treatment (data not shown). Also, pre-treatment with
parthenolide significantly stabilized phosphorylated p38 at
60 min (p = 0.02) (Figure 5E and 5F). Parthenolide pre-
treatment did not alter the total amount of all three pro-
teins in the cells (data not shown).
Figure 4 AS cells were pretreated with parthenolide or vehicle (placebo) for 1 h and then stimulated with TNFa/IL-1b for the
indicated time. Nuclear extracts were prepared and then analyzed by EMSA for both transcription factors NFB and AP-1. Representative
autoradiograph of EMSA for (A) NFB activation and (C) for AP-1 were presented. Summary graph of data for NFB (B) and AP-1 (D) activation
determined by densitometry from 4 time course experiments (n = 5 in each time point and condition), mean ± SEM are shown. Solid bar,
placebo; and open bars, parthenolide. Parthenolide pretreatment inhibited the activation of (B) NFB at 15, 30 and 60 min p = 0.003, p = 0.003
and p = 0.004, respectively), and (D) AP-1 at 30 min (p = 0.004).
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Figure 5 AS and IB3-1 cells were pretreated with parthenolide or vehicle (Placebo) for 1 h and then stimulated with IL-1b and/or
TNFa for the indicated time. Total cells protein extracts were prepared then analyzed for phosphorylated MAPK pERK, MAPK pJNK and the
MAPK pp38 in AS cells (A/B, C/D and E/F, respectively) and in IB3-1 cells (G/H, I/J and K/L respectively). Summary graph of data for
phosphorylated MAPKs determined by image analysis of densitometry from autoradiograph. Data show mean ± SEM of scan area of MAPK ERK,
JNK and p38 expression (n = 5 to 8 for each time point and condition) corrected for scan area of b-actin in the same gel lane. In both cell lines
Parthenolide inhibited cytokine-induced phosphorylation of ERK, but stabilized the phosphorylation of JNK and p38. Solid bar, placebo; open bar,
parthenolide-treated cells.
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In IB3-1 cells stimulated with TNFa alone, partheno-
lide pretreatment has the same effect as in AS cells sti-
mulated with TNFa/IL-1b. Parthenolide pretreatment
significantly inhibited phosphorylation and activation of
ERK 1 and 2 at 30 min (p = 0.04) (Figure 5G and 5H,
open bars), however pre-treatment with parthenolide
stabilized phosphorylated phospho-JNK at 30 min (p =
0.006) (Figure 5I and 5J, open bars), and also stabilized
the phosphorylated p38 at all time points 15, 30 and 60
min after TNFa stimulation (p = 0.0001, p = 0.05 and p
= 0.004, respectively) (Figure 5K and 5L, open bars).
Effects of parthenolide on IL-8 mRNA
Because phosphorylated p38 has been reported to stabi-
lize IL-8 mRNA, we wanted to determine if that
mechanism was operating concurrently with the inhibi-
tion of net IL-8 secretion caused by parthenolide.
Therefore, we evaluated the effect of the drug on IL-8
mRNA expression as determined by RT-PCR. ELISAs
were performed with supernatants from the same cells
used for the real time PCR experiments, to confirm that
parthenolide in fact inhibited IL-8 production during
each experiment. The results verified that parthenolide
inhibited IL-8 protein production in both AS and S cells
(Data not shown). Parthenolide pretreatment signifi-
cantly increased the content of IL-8 mRNA in TNFa/
IL-1b stimulated AS at 3 and 6 h (p = 0.001 and p =
0.00009, respectively) (Figure 6A) compared to cells
treated with vehicle alone (placebo, solid bars). In con-
trast, parthenolide treatment did not significantly
increase mRNA in S cells (Figure 6A, inset). These data
suggest that parthenolide treatment results in stabiliza-
tion of that mRNA which is transcribed. The increased
mRNA in the face of decreased protein production sug-
gests an additional inhibitory effect at a translational
level. In IB3-1 cells stimulated with TNFa alone, parthe-
nolide pretreatment leads to the inhibition of TNFa-
induced IL-8 mRNA accumulation (Figure 6B), whereas
in control S9 cells it did not significantly increase IL-8
mRNA accumulation (Figure 6B, inset).
Primary HTE cells rendered “CF like” with 20 μM
CFTRinh172 (21) were also evaluated. Figure 6C showed
that IL-8 mRNA accumulation in response to TNFa
alone is not significantly different between parthenolide
and DMSO pretreated unstimulated HTE cells (5.6 ±
1.69 vs. 4.54 ± 1.88 respectively), whereas Parthenolide
significantly inhibits the TNFa- induced increase in IL-8
secretion (p = 0.04) (Figure 6C, inset). In a separate
experiment AS cells were pretreated with parthenolide,
then one hour later stimulated with TNFa alone or IL-
1b/TNFa together. Parthenolide significantly increased
IL-8 mRNA accumulation in AS cells stimulated with
IL-1b/TNFa, whereas the parthenolide effects was not
observed when cells were stimulated with TNFa alone
(Figure 6D). In all cases, parthenolide significantly inhib-
ited IL-8 protein (data not shown).
Analysis of IL-8 promoter activity after pretreatment by
parthenolide and stimulation with both TNFa/IL-1b
Because the observation of increased IL-8 mRNA in AS
cells seems paradoxical in the face of inhibition of acti-
vation of the transcription factors AP-1 and NFB,
which are considered the most important regulators of
IL-8 gene expression, we sought to directly investigate
the influence of parthenolide on transcription indepen-
dently of possible effects on IL-8 mRNA stability or
translation. AS and S cell lines were transfected with a
plasmid driving expression of the firefly luciferase repor-
ter under control of the IL-8 promoter [23]. Firefly luci-
ferase activity was normalized against a constitutively
expressed Renilla luciferase reporter. AS and S cell lines
were pretreated with parthenolide or DMSO, then one
hour later stimulated with TNFa/IL-1b for 3 h. Super-
natants were collected and assessed by ELISA for IL-8
production and the cells were assessed for IL-8 promo-
ter activity. IL-8 promoter activity responded to TNFa/
IL-1b with 1.5-2 fold increases in luciferase expression
at 3 and 6 hrs respectively in AS cells (Figure 7). Parthe-
nolide inhibited this stimulated firefly luciferase expres-
sion as well as the basal expression without stimulation
(Figure 7), confirming inhibition of transcription. ELI-
SAs verified that parthenolide inhibited the production
of IL-8 protein in response to TNFa/IL-1b (data not
shown).
Discussion
Human bronchial epithelial cell lines with defective
CFTR expression and/or function have exaggerated IL-8
mRNA expression and protein secretion in response to
stimulation with TNF-a and IL-1b [7]. This result is in
agreement with most other studies of IL-8 mRNA in CF
cells and tissues [13,18,28,29]. We and others have pre-
viously shown that this is associated with increased and
prolonged activation of IKK and NFB in CF as com-
pared to non-CF cells [10,13,14,30]. The present results
confirm that inflammatory cytokine stimulation causes a
huge increase in IL-8 production and gene expression in
CF compared with control cells. Furthermore, we show
that the increased IL-8 production is also associated
with: 1) excessive and prolonged activation of AP-1 in
addition to NFB, and 2) excessive and prolonged acti-
vation of the MAP Kinases p38, JNK and ERK. Thus,
the MAPKs/AP-1 signaling pathways as well as the IKK/
NFB pathway shows exaggerated and prolonged activa-
tion after stimulation of cells with CF defects. Both
pathways likely contribute to the excessive amount of
IL-8 mRNA and excessive protein secretion which char-
acterizes CF.
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Figure 6 AS/S and IB3-1/S9 cells were pretreated with parthenolide or vehicle (placebo) for 1 h and then stimulated with IL-1b and/or
TNFa for the indicated time. Subsequently, media and total RNA were prepared and analyzed for protein production and mRNA expression.
The mRNA contents were normalized with for GAPDH and the results are given in relative units. (A) Parthenolide pretreatment significantly
increased IL-8 mRNA expression in AS cells at 3 and 6 h (p = 0.001 and p = 0.00009, respectively) compared to S cells (inset). (B) Parthenolide
pretreatment significantly inhibits IL-8 mRNA accumulation in IB3-1 cells at 3 h (p = 0.0004) compared to S9 cells (inset). (C) HTE cells were
treated with 20 μM CFTRinh172 for 3 weeks (media changed every other day). When cells were ready, the inhibitor was added to basal and
apical side and the media was replenished every day for 3 days. On the fourth day parthenolide or DMSO were added, one hour later cells were
stimulated with or without TNFa for 3 h. Parthenolide significantly decreased IL-8 secretion in HTEinh172 at 3 h (p = 0.004), whereas,
parthenolide pretreatment did not affect IL-8 mRNA accumulation (C, inset). (D) AS cells were pretreated with parthenolide or vehicle (placebo)
for 1 h and then stimulated with TNFa alone or TNFa/IL-1b for 3 h. Subsequently, media and total RNA were prepared and analyzed for mRNA
accumulation. The mRNA content was normalized with GAPDH and the results are given in relative units. Parthenolide pretreatment had no
significant changes on AS-stimulated with TNFa; however it significantly increased IL-8 mRNA accumulation in AS-stimulated with TNFa/IL-1b (p
= 0.0009). Results are shown as means ± SEM (n = 4-6 for each time point and condition).
Saadane et al. Journal of Inflammation 2011, 8:26
http://www.journal-inflammation.com/content/8/1/26
Page 11 of 15
IL-8 is a potent chemokine which attracts neutrophils
to the lung. An excess of this chemokine is believed to
make an important contribution to the excessive influx
of neutrophils that ultimately causes lung damage and
death in CF patients. A large body of evidence has
shown that the increased IL-8 secretion in CF is asso-
ciated with excessive activation of IKK and NFB
[10,12-14,30]. However, little is known about IL-8 regu-
lation in the context of mitogen-activated protein
kinases (MAPKs) and the transcription factor, activator
protein-1 (AP-1) in CF. Three MAPK pathways are
believed to contribute to IL-8 gene expression, the
extracellular-regulated protein kinase (ERK), JUN-N-
terminal protein kinase (JNK), and p38 MAPK [21]. To
our knowledge there are few studies that report a higher
ERK activation in CF cells [15], and no study about the
MAPK p38 or the transcription factor AP-1. Blau and
colleagues however did not demonstrate a prolonged
activation of ERK, which we believe to be of major
interest in CF disease. We believe that our paper for the
first time showed that all 3 MAPKs and AP-1 are dysre-
gulated and their activation is excessive and prolonged
in CF. All of these are activated by phosphorylation
through dual-specificity MAP kinase kinases, also
referred to as MKK [16,17,31]. Holtmann and colleagues
found that introduction of an activating mutation in
MKK6, increased p38 and, stabilized IL-8 mRNA and
further increased IL-8 protein formation induced by
NFB-inducing kinase (NIK) [16]. The active form of
the MAPK-activated protein kinase 2 (MK-2), a down-
stream substrate of the p38 MAPK pathway, also
induced mRNA stabilization. Negative mutants of MK-2
decreased mRNA stability [16,32]. This data suggest that
IL-1b and TNFa can induce IL-8 production through
Figure 7 Promoter activity after pretreatment with parthenolide and/or stimulation by TNFa/IL-1b. AS cell lines were transfected with a
plasmid-driving expression of the firefly luciferase reporter under control of IL-8 promoter. Then AS cells were pretreated with 40 μM
parthenolide or vehicle for 1 h and then stimulated with TNFa/IL-1b for the 3 and 6 h. At the indicated time media was collected and subject
to ELISA to determine IL-8 production. Cells were washed and then assayed for luciferase activity. Firefly luciferase activity was normalized
against a constitutively expressed Renilla luciferase reporter. Results are expressed as relative luciferase activity above control cells transfected and
pretreated with DMSO.
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simultaneous activation of MAPK cascades that regulate
AP-1 in addition to the IKK pathway, which activates
NFB [17]. Unlike NFB, AP-1 is not essential for tran-
scription of IL-8 but it is required for maximal gene
expression [16,17,24]. Further cooperation of these two
pathways resulting in maximal IL-8 secretion may be
due to activation of IKK by MAPK kinase kinase (also
called MEKK1), which also activates the three MAPKs
[29]. In addition, NFB and AP-1 modulate each other
and can function cooperatively [18,29,28,33] for rapid
and maximum transcriptional activation. However, their
activities are also rapidly down-regulated in normal cells
so that rigorous responses are often transient.
Our results clearly show that in epithelial cells with
CF defect, stimulation with TNFa alone or TNFa/IL-1b
results in marked increases in the amounts of phospho-
p38, phospho-ERK, and phospho-JNK p46/p54 as com-
pared to control cells. The time intervals at which the
phosphorylated intermediates of the different MAPKs
differ from each other, but for all three, phosphorylated
forms are present for longer intervals after stimulation
in “CF-Like” cells than in similarly stimulated “Wild-
Type-Like"cells. These results correlate with, and likely
account for the increased AP-1 observed at all time
intervals after stimulation in CF cells as compared to
non-CF cells. Thus, the CF defect seems to have similar
effects on the MAPK/AP-1 pathway as on the IKK/
NFB pathway. The persistent phosphorylation of all 3
MAPKs; ERK, JNK and p38 in cells with defective
CFTR, suggest that CF alters a phosphatase whose
decreased activity could explain the persistence of these
enzymes. Together, simultaneous and prolonged activa-
tion of these two transcription factors is very likely to
play a major role in the excessive and prolonged IL-8
production seen in CF cells and patients.
Parthenolide, a sesquiterpene lactone found in the
medicinal plant feverfew (Tanacetum parthenium) has
powerful anti-inflammatory properties [14,34,35]. We
have previously showed that parthenolide inhibits
inflammation in CF both in vivo and in vitro by inhibit-
ing IKK/NFB pathway. Parthenolide has been consid-
ered by some to be a specific inhibitor of the NFB
pathway [34-39]. During these studies, we wished to
determine the effects of this inhibitor on the MAPKs
and AP-1 pathway, because of the similar reactions and
likely cross-talk between the two pathways which lead
to formation of AP-1 and activation of NFB, respec-
tively. In agreement with previous results, we found that
parthenolide inhibited secretion of IL-8 protein by CF as
well as non-CF cells. Our new results show that parthe-
nolide inhibited ERK phosphorylation induced by
TNFa/IL-1b stimulation, and also inhibited AP-1 activa-
tion; but that phosphorylated p38 was preserved by this
inhibitor. Since phosphorylated p38 can play an
important role in stabilization of the mRNAs for pro-
inflammatory cytokines, we sought to dissect the possi-
ble effects of parthenolide on transcriptional activation
of the IL-8 promoter versus its net effects on IL-8
mRNA in cells stimulated with TNFa/IL-1b. Results
using a luciferase reporter construct show that parthe-
nolide inhibited transcription per se. However, using
real time PCR, we found that parthenolide pretreatment,
actually increased IL-8 mRNA in TNFa/IL-1b stimu-
lated cells. This is most likely a consequence of the pre-
servation of phosphorylated p38 caused by the drug
[16,32]. since phospho-p38 is known to play an impor-
tant role in modulating the effect of the AU rich
sequences that would otherwise destabilize pro-inflam-
matory cytokine mRNAs. In turn, the preservation of
phospho-p38 in the face of decreased phosphorylated
ERK suggests the possibility that parthenolide acts on a
phosphatase which specifically targets p38 [40,41]. The
results also suggest that parthenolide inhibits translation
of the IL-8 message, accounting for the apparent para-
dox of finding increased mRNA in the face of decreased
protein secretion.
The differences between cell lines is probably due to
the sources, however across each model parthenolide
pretreatment results in an inhibition of inflammatory
signaling in cells with CF defects.
Production of IL-8 and other pro-inflammatory cyto-
kines is also governed by mechanisms regulating in their
mRNA half-lives. Several reports have shown that IL-8
mRNA degradation is modulated by AU-rich sequences
present in the 3’UTR of IL-8 mRNA [23,28,42]. These
sequences function as potent destabilizing elements that
cause rapid decay of the transcripts. Furthermore, a
recently identified family of genes called micro-inhibi-
tory RNAs (miRNAs) has been shown to regulate pro-
tein expression mainly at the post-transcriptional level
[43], and has been shown to be dysregulated in several
inflammatory diseases including psoriasis, rheumatoid
arthritis and asthma [44,45]. The miRNA/mRNA inter-
action occurs within the 3’UTR of the target mRNA and
decreases protein translation. Since our results suggest
that parthenolide also inhibits translation (see below),
we speculate that this may involve stabilization of these
inhibitory miRNAs, which in turn inhibits IL-8 mRNA
translation. This hypothesis would best explain our
results, which showed decreased IL-8 protein secretion
despite increased message concomitantly with stabiliza-
tion of phospho-p38.
Overall, the results in three different cellular models
of CF show remarkable similarity in the ways that multi-
ple different pathways of transcription factor signaling
are affected by the CF defect. In response to physiologic
stimulation, phosphorylation and activation of multiple
MAPKs is greater and persists for longer in CF airway
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epithelial cells as compared to non-CF airway epithelial
cells. The termination of the activities of MAPKs and
IKK is normally insured by dual specificity phosphatases
(DUSP), also called MAP kinase phosphatase (MKP)
[46-48].
Our data showing increased activity of multiple kinase
pathways may therefore suggest that decreased expres-
sion or function of CFTR somehow decreases activity of
a multi-specific protein phosphatase [49]. Although this
particular study has focused only on one important pro-
inflammatory cytokine, IL-8, it is likely that many other
genes are also over-expressed in CF as a consequence of
the dysregulation of these signaling pathways.
Conclusions
Our results suggest that 1) in addition to IKK/NFB
pathway, MAPKs and AP-1 are also dysregulated in CF
epithelial cells, and 2) the effects of a widely used inhibi-
tor, parthenolide, are less specific than previously
believed. However, the results also suggest that this type
of compound, which simultaneously targets multiple sig-
naling pathways, may have beneficial effects in CF and
other diseases in which multiple mechanisms that
should control inflammation are disrupted.
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